OncoZenge AB Statistics
OncoZenge AB (8LY) Stock Statistics & Valuation Metrics
Total Valuation
OncoZenge AB has a market cap or net worth of EUR 8.07M. The enterprise value is EUR 108.32M.
- Market Cap
- EUR 8.07M
- Enterprise Value
- EUR 108.32M
Share Statistics
OncoZenge AB has 27,601,244 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 27,601,244
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
OncoZenge AB’s return on equity (ROE) is 27.16 and return on invested capital (ROIC) is -229.57%.
- Return on Equity (ROE)
- 27.16
- Return on Assets (ROA)
- -1.04
- Return on Invested Capital (ROIC)
- -229.57%
- Return on Capital Employed (ROCE)
- -2.30
- Revenue Per Employee
- 2.66M
- Profits Per Employee
- -15.94M
- Employee Count
- 1
- Asset Turnover
- 0.17
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of OncoZenge AB is -1.36. OncoZenge AB’s PEG ratio is 0.01.
- PE Ratio
- -1.36
- PS Ratio
- 7.74
- PB Ratio
- 2.51
- Price to FCF
- -3.23
- Price to Operating Cash Flow
- -1.74
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, OncoZenge AB had revenue of 2.66M and earned -15.94M in profits. Earnings per share was -1.31.
- Revenue
- 2.66M
- Gross Profit
- -4.84M
- Operating Income
- -15.87M
- Pretax Income
- -15.94M
- Net Income
- -15.94M
- EBITDA
- -15.87M
- Earnings Per Share (EPS)
- -1.31
Cash Flow
In the last 12 months, operating cash flow was -26.96M and capital expenditures 13.06M, giving a free cash flow of -13.90M billion.
- Operating Cash Flow
- -26.96M
- Free Cash Flow
- -13.90M
- Free Cash Flow per Share
- -0.95
Dividends & Yields
OncoZenge AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -30.92%
- Earnings Yield
- -68.04%
Stock Price Statistics
- Beta
- 0.71
- 52-Week Price Change
- -37.05%
- 50-Day Moving Average
- 0.28
- 200-Day Moving Average
- 0.42
- Relative Strength Index (RSI)
- 50.47
- Average Volume (3m)
- ―
Important Dates
OncoZenge AB upcoming earnings date is Feb 18, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
OncoZenge AB as a current ratio of 1.01, with Debt / Equity ratio of -1277.68%
- Current Ratio
- 1.01
- Quick Ratio
- 1.01
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- -0.24
- Interest Coverage Ratio
- -93.91
Taxes
In the past 12 months, OncoZenge AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
OncoZenge AB EV to EBITDA ratio is -0.94, with an EV/FCF ratio of -1.49.
- EV to Sales
- 3.56
- EV to EBITDA
- -0.94
- EV to Free Cash Flow
- -1.49
- EV to Operating Cash Flow
- -0.77
Balance Sheet
OncoZenge AB has EUR 24.30M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 24.30M billion.
- Cash & Marketable Securities
- EUR 24.30M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 24.30M
- Net Cash Per Share
- EUR 0.88
- Tangible Book Value Per Share
- EUR 0.81
Margins
Gross margin is 67.64%, with operating margin of -531.19%, and net profit margin of -549.70%.
- Gross Margin
- 67.64%
- Operating Margin
- -531.19%
- Pretax Margin
- -549.70%
- Net Profit Margin
- -549.70%
- EBITDA Margin
- -378.22%
- EBIT Margin
- -531.19%
Analyst Forecast
The average price target for OncoZenge AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 122.10%
- EPS Growth Forecast
- -242.46%

